Saturday, December 25, 2021 9:41:04 AM
Missling suspects that:
1. 2-73 is a potent S1 agonist
2. Agonizing S1 can be therapeutic
3. Our clinical trials are showing true responses
4. The variation in responses (no response in a few, some response in most, a big response in a few) can be explained by, among other factors, genetics
The company's effort to track the SIGMAR1 mRNA biomarker is being done to prove #1. Its work with Ariana is to prove #4. Our trials are designed to prove all four and get regulatory approval. Watch for trial results. Ignore the typical MB nonsense. Stock boards have a lot of it (you may have noticed
).
1. 2-73 is a potent S1 agonist
2. Agonizing S1 can be therapeutic
3. Our clinical trials are showing true responses
4. The variation in responses (no response in a few, some response in most, a big response in a few) can be explained by, among other factors, genetics
The company's effort to track the SIGMAR1 mRNA biomarker is being done to prove #1. Its work with Ariana is to prove #4. Our trials are designed to prove all four and get regulatory approval. Watch for trial results. Ignore the typical MB nonsense. Stock boards have a lot of it (you may have noticed
).
